TeamDrive
RUS

Russian authorities proposed to introduce liability for false drug prices

13 September 2017

GMP News

The Russian Ministry of Health proposed to introduce administrative liability for legal entities in case of false information provided during the state registration/re-registration of maximum selling prices for the medicines included in list of vital and essential drugs (VED).

Currently, the law does not stipulate any liability of legal entities (holders or owners of the registration certificate of medicinal product for human use, or party authorized by such holders or owners) for providing false information at the state registration (re-registration) of the manufacturer’s maximum selling prices for medicinal products included in the list of vital and essential drugs.

The draft federal law provides for amending the Russian Code of Administrative Offenses for submission of false information by the holder or owner of the registration certificate of medicinal product for human use (party authorized by such holders or owners) during the state registration (re-registration) of the manufacturer’s maximum selling prices for medicinal products included in the list of VED, changes to the register’s entry on the state registration of the manufacturer’s maximum selling price for medicinal product, which affected the results of economic analysis of the manufacturer’s maximum selling price of medicinal product for human use and led to unreasonable increase of the manufacturer’s maximum selling price for medicinal product.

According to the draft law, these offenses would entail the imposition of administrative fine on legal entities in the twofold the excess of the proceeds received from the sale of medicinal products as a result of unreasonable increase of the manufacturer’s maximum selling prices for medicinal products during the entire period in which the offense was committed, but no more than one year.

Source


Previous publication Next publication

Media Center

  • 21 November 2017

    Russian pharmaceutical market reaches 863 billion rubles in Q1-Q3

    According to AlphaRM, September 2017 ended with the growth in the retail segment and fall in the public segment of the pharmaceutical market compared both to the previous month (+11% and -21%, respectively) and the past year (+1% and -21%, respectively).

  • 21 November 2017

    Russian pharmaceutical industry strives for new achievements

    Over the past 8 years, since the beginning of the active implementation of the “Pharma 2020” program, the right vector of development has been set and, today, the Russian pharmaceutical industry is the fastest growing sector in the country. In 2016, the Russian pharmaceutical companies were developing at a much more dynamic pace than their foreign counterparts. In that year, their revenues amounted to 314.5 billion rubles, that is 23.7% more than in 2015. At the same time, the volume of drugs imported to the Russian market increased by 8.1% over the year to reach 493.1 billion rubles.

  • 20 November 2017

    Tweet up? Twitter move to 280 characters opens new frontiers for pharma, agency says

    Will pharma learn to love Twitter now that it’s doubled its character limit to 280? Last week, the popular social media platform announced it would offer all users twice as much space, and at least one pharma ad agency says industry marketers should be glad.

  • 20 November 2017

    Biosimilars Raise Analytical and Policy Challenges

    FDA approved seven biosimilars through October 2017, based on the agency’s now well-established “step-wise” approach for assessing analytical similarity through biological and physiochemical product characterization. Still the debate continues over biosimilar naming, interchangeability, and patent protection, as well as lingering concerns in the medical community about the safety of switching patients to new therapies.

Read more